Patents Assigned to CRYSTAL PHARMATECH CO., LTD
-
Patent number: 10246418Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.Type: GrantFiled: June 8, 2016Date of Patent: April 2, 2019Assignee: Crystal Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
-
Patent number: 10246437Abstract: The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The novel crystalline forms of Neratinib maleate in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.Type: GrantFiled: January 8, 2016Date of Patent: April 2, 2019Assignee: Crystal Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
-
Patent number: 10233144Abstract: The present disclosure relates to a novel crystalline form of a compound of formula (I), preparation method and use thereof. The novel crystalline form in the present disclosure has good stability, low hygroscopicity, and remarkable purification effect in process. The novel crystalline form of the compound of formula (I) provided by the present disclosure can be used for the preparation of the drug for treating heart failure.Type: GrantFiled: March 18, 2016Date of Patent: March 19, 2019Assignee: Crystal Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Shu Yu, Xiaoyu Zhang, Liang Zhang
-
Patent number: 10196395Abstract: The present disclosure relates to crystalline Form ? of a compound of formula (I) used for preparing a blood-cancer drug and preparation method thereof. The crystalline Form ? in the present disclosure has better stability, and its solubility and hygroscopicity meet the requirements of medical use. Form ? has simple preparation method and low manufacturing cost, and provides great value to future optimization and development of this drug.Type: GrantFiled: February 1, 2016Date of Patent: February 5, 2019Assignee: Crystal Pharmatech Co., LtdInventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Nan Xia, Xiaoyu Zhang
-
Publication number: 20180354916Abstract: The present disclosure relates to a preparation method of a trisodium AHU-377 and Valsartan co-crystal hydrate Form II. The preparation method comprises: firstly, preparing a clear solution of trisodium AHU-377 and Valsartan, the solvent of the clear solution comprises an anti-solvent and a good solvent of the target product Form II, and the boiling point of the good solvent is lower than that of the anti-solvent; secondly, evaporating the solution under vacuum to remove the good solvent and water from the system; and finally, optionally adding seed crystals of Form II or not and replenishing a mixture of water and a carrier solvent for stirring for crystallization. The method of the present disclosure can prepare Form II successfully, and the process is consistent and controllable. The obtained Form II product has high chemical purity, crystalline purity and good flowability; and the process can be scaled up, and meets the requirements of large-scale production.Type: ApplicationFiled: November 10, 2016Publication date: December 13, 2018Applicant: CRYSTAL PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Liang ZHANG
-
Patent number: 10138250Abstract: The present invention relates to novel crystalline forms of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide (compound I), its salts, and process for preparation thereof. Crystalline forms in the present invention have good stability, low hygroscopicity, good processability, easy treatability and other favorable properties. In addition, the process is simple, low cost, and has an important value for future optimization and development of the drug.Type: GrantFiled: May 21, 2018Date of Patent: November 27, 2018Assignee: Crystal Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Xiaoyu Zhang
-
Patent number: 10138239Abstract: A preparation method of PCI-32765 crystalline form A, which comprises the following steps: 1) dissolving free base of PCI-32765 in a good solvent; 2) the solution prepared by Step 1) is dropwise added into an anti-solvent, stirred and added seed crystal of PCI-32765 Form A; Or the solution prepared by Step 1) is dropwise added into the suspension containing seed crystal of PCI-32765 Form A; 3) solution obtained by step 2) is continuously stirred and aged until crystal transformation is completed, then the crystal slurry is obtained; 4) crystal slurry in step 3) is filtered, washed, and dried to obtain the powder of PCI-32765 Form A. The preparation method of crystalline Form A provided by the present disclosure is a simple process and can be easily controlled, scaled up stably and conducted reliably. The process has high yield, good impurity removing capacity and is environmentally friendly.Type: GrantFiled: March 18, 2016Date of Patent: November 27, 2018Assignee: Crystal Pharmatech Co. LTDInventors: Minhua Chen, Yanfeng Zhang, Liang Zhang, Shulin Ji
-
Publication number: 20180265495Abstract: The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The maleate novel crystalline forms of compound of Formula (I) in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.Type: ApplicationFiled: January 8, 2016Publication date: September 20, 2018Applicant: CRYSTAL PHARMATECH CO., LTDInventors: Minhua CHEN, Yanfeng ZHANG, Xiaojuan DIAO, Xiaoyu ZHANG
-
Publication number: 20180230136Abstract: The present disclosure provides crystalline form A of 3-(6-(1-(2, 2-difluorobenzo [d] [1, 3] dioxo-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and process of preparation thereof. The crystalline form A has low hygroscopicity, good stability, is convenient to store. It has higher solubility than that of prior art and therefore plays an important role in further optimization and development of the drug.Type: ApplicationFiled: August 11, 2016Publication date: August 16, 2018Applicant: CRYSTAL PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Kai LIU, Po ZOU, Xiaoyu ZHANG
-
Publication number: 20180170958Abstract: The present invention relates to crystalline Form A of obeticholic acid and the preparation method thereof. The present invention provides Form A having characteristic peaks at 2theta value of 4.9°±0.2°, 5.2°±0.2°, 9.9°±0.2°. The present invention provides a novel crystalline form of obeticholic acid, which has good stability, good processability and other favorable properties, and is suitable for storage and usage as a final product. In addition, the preparation method is simple, low cost, and has great value for the future optimization and development of obeticholic acid.Type: ApplicationFiled: December 30, 2015Publication date: June 21, 2018Applicant: Crystal Pharmatech Co., Ltd.Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaojuan Diao, Xiaoyu Zhang
-
Publication number: 20180170919Abstract: The present disclosure relates to novel crystalline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl-4?-(trifluoromethoxy) [1,1?-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compound of formula (I) has low hygroscopicity, is convenient to store, has better stability than that of diphosphonate in prior art, can avoid the risk of crystal transformation in the development and production of the drug. The preparation method is simple, has low cost, and has important value for further optimization and development of the drug.Type: ApplicationFiled: March 30, 2016Publication date: June 21, 2018Applicant: CRYSTAL PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Fei LU, Xiaoyu ZHANG
-
Patent number: 9994579Abstract: The present invention relates to novel crystalline forms of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-car boxylic acid dimethylamide(compound I), its salts, and process for preparation thereof. Crystalline forms in the present invention have good stability, low hygroscopicity, good processability, easy treatability and other favorable properties. In addition, the process is simple, low cost, and has an important value for future optimization and development of the drug.Type: GrantFiled: December 11, 2015Date of Patent: June 12, 2018Assignee: Crystal Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Kai Liu, Jiaoyang Li, Xiaoyu Zhang
-
Publication number: 20180155291Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.Type: ApplicationFiled: June 8, 2016Publication date: June 7, 2018Applicant: CRYSTAL PHARMATECH CO., LTDInventors: Minhua CHEN, Yanfeng ZHANG, Xiaojuan DIAO, Xiaoyu ZHANG
-
Patent number: 9969701Abstract: Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.Type: GrantFiled: December 19, 2014Date of Patent: May 15, 2018Assignees: Crystal Pharmatech Co., Ltd., Suzhou Pengxu Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li
-
Patent number: 9957240Abstract: Novel crystalline Forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3?-methyl-T-(pentanoyl{2?-(tetrazol-5-ylate)biphenyl-4?-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.Type: GrantFiled: December 8, 2015Date of Patent: May 1, 2018Assignees: CRYSTAL PHARMATECH CO., LTD, SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Jiaoyang Li, Peng Wang, Pixu Li
-
Publication number: 20180086695Abstract: The present disclosure relates to a novel crystalline form of a compound of formula (I), preparation method and use thereof. The novel crystalline form in the present disclosure has good stability, low hygroscopicity, and remarkable purification effect in process. The novel crystalline form of the compound of formula (I) provided by the present disclosure can be used for the preparation of the drug for treating heart failure.Type: ApplicationFiled: March 18, 2016Publication date: March 29, 2018Applicant: CRYSTAL PHARMATECH CO., LTDInventors: Minhua CHEN, Yanfeng ZHANG, Chaohui YANG, Shu YU, Xiaoyu ZHANG, Liang ZHANG
-
Publication number: 20180072733Abstract: The present disclosure relates to crystalline Form ? of a compound of formula (I) used for preparing a blood-cancer drug and preparation method thereof. The crystalline Form ? in the present disclosure has better stability, and its solubility and hygroscopicity meet the requirements of medical use. Form ? has simple preparation method and low manufacturing cost, and provides great value to future optimization and development of this drug.Type: ApplicationFiled: February 1, 2016Publication date: March 15, 2018Applicant: CRYSTAL PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Xiaojuan DIAO, Nan XIA, Xiaoyu ZHANG
-
Publication number: 20180065958Abstract: A preparation method of PCI-32765 crystalline form A, which comprises the following steps: 1) dissolving free base of PCI-32765 in a good solvent; 2) the solution prepared by Step 1) is dropwise added into an anti-solvent, stirred and added seed crystal of PCI-32765 Form A; Or the solution prepared by Step 1) is dropwise added into the suspension containing seed crystal of PCI-32765 Form A; 3) solution obtained by step 2) is continuously stirred and aged until crystal transformation is completed, then the crystal slurry is obtained; 4) crystal slurry in step 3) is filtered, washed, and dried to obtain the powder of PCI-32765 Form A. The preparation method of crystalline Form A provided by the present disclosure is a simple process and can be easily controlled, scaled up stably and conducted reliably. The process has high yield, good impurity removing capacity and is environmentally friendly.Type: ApplicationFiled: March 18, 2016Publication date: March 8, 2018Applicant: CRYSTAL PHARMATECH CO., LTDInventors: Minhua CHEN, Yanfeng ZHANG, Liang ZHANG, Shulin JI
-
Publication number: 20180057498Abstract: The present disclosure relates to novel co-crystals of a CDK inhibitor and an MEK inhibitor and the preparation methods thereof. Specifically, the present disclosure provides hydrates or anhydrates which are named as Form I, Form II and Form III. The novel co-crystals provided in the present disclosure have good stability, low hygroscopicity and high solubility, and have an important value for further optimization and development of the drug.Type: ApplicationFiled: April 1, 2016Publication date: March 1, 2018Applicant: CRYSTAL PHARMATECH CO., LTDInventors: Minhua CHEN, Yanfeng ZHANG, Qiyue LIU, Nan XIA, Chaohui YANG, Xiaoyu ZHANG
-
Publication number: 20180044342Abstract: The present disclosure relates to novel crystalline forms of JAK inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis. The novel crystalline forms in the present disclosure have good stability and remarkable purification effect in process, moreover, its solubility and hygroscopicity meet the requirements for medical use. The preparation method of novel crystalline forms is simple, low cost, and has an important value for future optimization and development of the drug.Type: ApplicationFiled: March 11, 2016Publication date: February 15, 2018Applicant: CRYSTAL PHARMATECH CO., LTDInventors: Minhua CHEN, Yanfeng ZHANG, Xiaojuan DIAO, Nan XIA, Xiaoyu ZHANG